{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:05Z","timestamp":1788316805770,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is limited consensus regarding the optimal treatment of insomnia. The recent introduction of orexin receptor antagonists (ORA) has increased the available treatment options. However, the prescribing patterns of hypnotics in Japan have not been comprehensively assessed. We performed analyses of a claims database to investigate the real-world use of hypnotics for treating insomnia in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were retrieved for outpatients (aged\u2009\u2265\u200920 to\u2009&lt;\u200975\u00a0years old) prescribed\u2009\u2265\u20091 hypnotic for a diagnosis of insomnia between April 1<jats:sup>st<\/jats:sup>, 2009 and March 31<jats:sup>st<\/jats:sup>, 2020, with\u2009\u2265\u200912\u00a0months of continuous enrolment in the JMDC Claims Database. Patients were classified as new or long-term users of hypnotics. Long-term use was defined as prescription of the same mechanism of action (MOA) for\u2009\u2265\u2009180\u00a0days. We analyzed the trends (2010\u20132019) and patterns (2018\u20132019) in hypnotics prescriptions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analyzed data for 130,177 new and 91,215 long-term users (2010\u20132019). Most new users were prescribed one MOA per year (97.1%\u201397.9%). In 2010, GABA<jats:sub>A<\/jats:sub>-receptor agonists (benzodiazepines [BZD] or z-drugs) were prescribed to 94.0% of new users. Prescriptions for BZD declined from 54.8% of patients in 2010 to 30.5% in 2019, whereas z-drug prescriptions remained stable (~\u200940%). Prescriptions for melatonin receptor agonist increased slightly (3.2% to 6.3%). Prescriptions for ORA increased over this time from 0% to 20.2%. Prescriptions for BZD alone among long-term users decreased steadily from 68.3% in 2010 to 49.7% in 2019. Prescriptions for ORA were lower among long-term users (0% in 2010, 4.3% in 2019) relative to new users. Using data from 2018\u20132019, multiple (\u2265\u20092) MOAs were prescribed to a higher proportion of long-term (18.2%) than new (2.8%) users. The distribution of MOAs according to psychiatric comorbidities, segmented by age or sex, revealed higher proportions of BZD prescriptions in elderly (new and long-term users) and male (new users) patients in all comorbidity segments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Prescriptions for hypnotics among new and long-term users in Japan showed distinct patterns and trends. Further understanding of the treatment options for insomnia with accumulating evidence for the risk\u2013benefit balance might be beneficial for physicians prescribing hypnotics in real-world settings.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-023-04683-2","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T18:26:24Z","timestamp":1682015184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database"],"prefix":"10.1186","volume":"23","author":[{"given":"Shoki","family":"Okuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Tokita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"4683_CR1","doi-asserted-by":"publisher","first-page":"15026","DOI":"10.1038\/nrdp.2015.26","volume":"1","author":"CM Morin","year":"2015","unstructured":"Morin CM, Drake CL, Harvey AG, Krystal AD, Manber R, Riemann D, et al. Insomnia disorder. Nat Rev Dis Primers. 2015;1:15026. https:\/\/doi.org\/10.1038\/nrdp.2015.26.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"4683_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7326\/m15-2175","volume":"165","author":"A Qaseem","year":"2016","unstructured":"Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125\u201333. https:\/\/doi.org\/10.7326\/m15-2175.","journal-title":"Ann Intern Med"},{"issue":"6","key":"4683_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.12594","volume":"26","author":"D Riemann","year":"2017","unstructured":"Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675\u2013700. https:\/\/doi.org\/10.1111\/jsr.12594.","journal-title":"J Sleep Res"},{"issue":"2","key":"4683_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307\u201349. https:\/\/doi.org\/10.5664\/jcsm.6470.","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"4683_CR5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1177\/0269881110379307","volume":"24","author":"SJ Wilson","year":"2010","unstructured":"Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577\u2013601. https:\/\/doi.org\/10.1177\/0269881110379307.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"4683_CR6","doi-asserted-by":"publisher","first-page":"e12635","DOI":"10.2196\/12635","volume":"3","author":"D Sato","year":"2019","unstructured":"Sato D, Sutoh C, Seki Y, Nagai E, Shimizu E. Treatment preferences for internet-based cognitive behavioral therapy for insomnia in Japan: online survey. JMIR Form Res. 2019;3(2):e12635. https:\/\/doi.org\/10.2196\/12635.","journal-title":"JMIR Form Res"},{"key":"4683_CR7","unstructured":"Ministry of Health, Labour and Welfare. Comprehensive Research Project on Scientific Research\/Countermeasures Concerning Persons with disabilities \u201cStudy group on clinical guidelines for proper use and dosage decrease\/discontinuation of hypnotics\u201d and The Japanese Society of Sleep Research\/Working group for formulating guidelines on hypnotics use version, clinical guidelines for proper use and withdrawal of hypnotics. 2013. Available at: http:\/\/www.jssr.jp\/data\/pdf\/suiminyaku-guideline.pdf (in Japanese). Accessed 20 Apr 2022."},{"key":"4683_CR8","unstructured":"International Narcotics Control Board, United Nations. Report of the International Narcotics Control Board for 2015 (E\/INCB\/2015\/1). Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes. Indispensable, adequately available and not unduly restricted. Available at: https:\/\/www.incb.org\/documents\/Publications\/AnnualReports\/AR2015\/English\/Supplement-AR15_availability_English.pdf. Accessed 20 Apr 2022."},{"issue":"4","key":"4683_CR9","doi-asserted-by":"publisher","first-page":"e0174730","DOI":"10.1371\/journal.pone.0174730","volume":"12","author":"K Donnelly","year":"2017","unstructured":"Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PLoS ONE. 2017;12(4):e0174730. https:\/\/doi.org\/10.1371\/journal.pone.0174730.","journal-title":"PLoS ONE"},{"key":"4683_CR10","doi-asserted-by":"publisher","first-page":"e6231","DOI":"10.1136\/bmj.e6231","volume":"345","author":"S Billioti de Gage","year":"2012","unstructured":"Billioti de Gage S, B\u00e9gaud B, Bazin F, Verdoux H, Dartigues JF, P\u00e9r\u00e8s K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231. https:\/\/doi.org\/10.1136\/bmj.e6231.","journal-title":"BMJ"},{"key":"4683_CR11","doi-asserted-by":"publisher","unstructured":"Campbell R, Chabot I, Rousseau B, Bridge D, Nicol G, Meier G. Understanding the unmet needs in insomnia treatment: a systematic literature review of real-world evidence. Int J Neurosci. 2021:1\u201315. https:\/\/doi.org\/10.1080\/00207454.2021.1995383.","DOI":"10.1080\/00207454.2021.1995383"},{"key":"4683_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency. PMDA alert for proper use of drugs: dependence associated with benzodiazepine receptor agonists. 2017.\u00a0Available at:\u00a0https:\/\/www.pmda.go.jp\/files\/000217228.pdf. Accessed 20 Apr 2022."},{"issue":"2","key":"4683_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1124\/pr.117.014381","volume":"70","author":"T Atkin","year":"2018","unstructured":"Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev. 2018;70(2):197\u2013245. https:\/\/doi.org\/10.1124\/pr.117.014381.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"4683_CR14","first-page":"29","volume":"96","author":"E Matheson","year":"2017","unstructured":"Matheson E, Hainer BL. Insomnia: pharmacologic therapy. Am Fam Physician. 2017;96(1):29\u201335.","journal-title":"Am Fam Physician"},{"key":"4683_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/nss.S76910","volume":"8","author":"JL Norman","year":"2016","unstructured":"Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia \u2013 critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239\u201347. https:\/\/doi.org\/10.2147\/nss.S76910.","journal-title":"Nat Sci Sleep"},{"key":"4683_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.genhosppsych.2019.11.008","volume":"62","author":"M Enomoto","year":"2020","unstructured":"Enomoto M, Kitamura S, Tachimori H, Takeshima M, Mishima K. Long-term use of hypnotics: analysis of trends and risk factors. Gen Hosp Psychiatry. 2020;62:49\u201355. https:\/\/doi.org\/10.1016\/j.genhosppsych.2019.11.008.","journal-title":"Gen Hosp Psychiatry"},{"key":"4683_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.drugalcdep.2015.11.010","volume":"158","author":"Y Okumura","year":"2016","unstructured":"Okumura Y, Shimizu S, Matsumoto T. Prevalence, prescribed quantities, and trajectory of multiple prescriber episodes for benzodiazepines: a 2-year cohort study. Drug Alcohol Depend. 2016;158:118\u201325. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.11.010.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"4683_CR18","doi-asserted-by":"publisher","first-page":"e029641","DOI":"10.1136\/bmjopen-2019-029641","volume":"9","author":"A Takano","year":"2019","unstructured":"Takano A, Ono S, Yamana H, Matsui H, Matsumoto T, Yasunaga H, et al. Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan. BMJ Open. 2019;9(7):e029641. https:\/\/doi.org\/10.1136\/bmjopen-2019-029641.","journal-title":"BMJ Open"},{"key":"4683_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.psychres.2016.01.040","volume":"237","author":"N Takeshima","year":"2016","unstructured":"Takeshima N, Ogawa Y, Hayasaka Y, Furukawa TA. Continuation and discontinuation of benzodiazepine prescriptions: a cohort study based on a large claims database in Japan. Psychiatry Res. 2016;237:201\u20137. https:\/\/doi.org\/10.1016\/j.psychres.2016.01.040.","journal-title":"Psychiatry Res"},{"key":"4683_CR20","unstructured":"JMDC. JMDC Claims Database. Available at: https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database. Accessed 20 Apr 2022."},{"issue":"8","key":"4683_CR21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","volume":"30","author":"TA Kurko","year":"2015","unstructured":"Kurko TA, Saastamoinen LK, T\u00e4hk\u00e4p\u00e4\u00e4 S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns - a systematic review of register-based studies. Eur Psychiatry. 2015;30(8):1037\u201347. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.09.003.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"4683_CR22","doi-asserted-by":"publisher","first-page":"e00896","DOI":"10.1002\/prp2.896","volume":"10","author":"A Woods","year":"2022","unstructured":"Woods A, Begum M, Gonzalez-Chica D, Bernardo C, Hoon E, Stocks N. Long-term benzodiazepines and z-drug prescribing in Australian general practice between 2011 and 2018: a national study. Pharmacol Res Perspect. 2022;10(1):e00896. https:\/\/doi.org\/10.1002\/prp2.896.","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"4683_CR23","doi-asserted-by":"publisher","first-page":"e113753","DOI":"10.1371\/journal.pone.0113753","volume":"9","author":"Y Takaesu","year":"2014","unstructured":"Takaesu Y, Komada Y, Asaoka S, Kagimura T, Inoue Y. Factors associated with long-term use of hypnotics among patients with chronic insomnia. PLoS ONE. 2014;9(11):e113753. https:\/\/doi.org\/10.1371\/journal.pone.0113753.","journal-title":"PLoS ONE"},{"issue":"2","key":"4683_CR24","doi-asserted-by":"publisher","first-page":"18m12149","DOI":"10.4088\/JCP.18m12149","volume":"80","author":"HM Kim","year":"2019","unstructured":"Kim HM, Gerlach LB, Van T, Yosef M, Conroy DA, Zivin K. Predictors of long-term and high-dose use of zolpidem in veterans. J Clin Psychiatry. 2019;80(2):18m12149. https:\/\/doi.org\/10.4088\/JCP.18m12149.","journal-title":"J Clin Psychiatry"},{"key":"4683_CR25","doi-asserted-by":"publisher","first-page":"595623","DOI":"10.3389\/fpsyt.2020.595623","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu L, Jian P, Zhou Y, Zhou J, Jia L, Tang M, Zhang R, Tang Y. Is the long-term use of benzodiazepines associated with worse cognition performance in highly educated older adults? Front Psychiatry. 2020;11:595623. https:\/\/doi.org\/10.3389\/fpsyt.2020.595623.","journal-title":"Front Psychiatry"},{"issue":"3","key":"4683_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40801-021-00244-9","volume":"8","author":"K Inada","year":"2021","unstructured":"Inada K, Enomoto M, Yamato K, Mishima K. Prescribing pattern of hypnotic medications in patients initiating treatment at Japanese hospitals: a nationwide, retrospective, longitudinal, observational study using a claims database. Drugs Real World Outcomes. 2021;8(3):277\u201388. https:\/\/doi.org\/10.1007\/s40801-021-00244-9.","journal-title":"Drugs Real World Outcomes"},{"issue":"Supplement","key":"4683_CR27","doi-asserted-by":"publisher","first-page":"s138","DOI":"10.3820\/jjpe.23.s138","volume":"23","author":"N Matsuyama","year":"2018","unstructured":"Matsuyama N, Takeuchi M, Watanabe N, Kawakami K. Prescribing pattern of an orexin receptor antagonist and non-benzodiazepines using a large claims database (in Japanese). Jpn J Pharmacoepidemiol. 2018;23(Supplement):s138\u20139. https:\/\/doi.org\/10.3820\/jjpe.23.s138.","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"4683_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12888-021-03046-z","volume":"21","author":"K Yamato","year":"2021","unstructured":"Yamato K, Inada K, Enomoto M, Marumoto T, Takeshima M, Mishima K. Patterns of hypnotic prescribing for residual insomnia and recurrence of major depressive disorder: a retrospective cohort study using a Japanese health insurance claims database. BMC Psychiatry. 2021;21:40. https:\/\/doi.org\/10.1186\/s12888-021-03046-z.","journal-title":"BMC Psychiatry"},{"key":"4683_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jsmc.2022.03.004","volume":"17","author":"GS Brewster","year":"2022","unstructured":"Brewster GS, Riegel B, Gehrman PR. Insomnia in the older adult. Sleep Med Clin. 2022;17:233\u20139. https:\/\/doi.org\/10.1016\/j.jsmc.2022.03.004.","journal-title":"Sleep Med Clin"},{"key":"4683_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2188\/jea.10.79","volume":"10","author":"Y Doi","year":"2000","unstructured":"Doi Y, Minowa M, Okawa M, Uchiyama M. Prevalence of sleep disturbance and hypnotic medication use in relation to sociodemographic factors in the general Japanese adult population. J Epidemiol. 2000;10:79\u201386. https:\/\/doi.org\/10.2188\/jea.10.79.","journal-title":"J Epidemiol"},{"key":"4683_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11920-016-0717-y","volume":"18","author":"S Creado","year":"2016","unstructured":"Creado S, Plante DT. An update on the use of sedative-hypnotic medications in psychiatric disorders. Curr Psychiatry Rep. 2016;18:78. https:\/\/doi.org\/10.1007\/s11920-016-0717-y.","journal-title":"Curr Psychiatry Rep"},{"key":"4683_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.mcna.2014.06.009","volume":"98","author":"EL Sutton","year":"2014","unstructured":"Sutton EL. Psychiatric disorders and sleep issues. Med Clin North Am. 2014;98:1123\u201343. https:\/\/doi.org\/10.1016\/j.mcna.2014.06.009.","journal-title":"Med Clin North Am"},{"issue":"2","key":"4683_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5665\/sleep.3410","volume":"37","author":"SM Bertisch","year":"2014","unstructured":"Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999\u20132010. Sleep. 2014;37(2):343\u20139. https:\/\/doi.org\/10.5665\/sleep.3410.","journal-title":"Sleep"},{"issue":"10","key":"4683_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/ijerph13100955","volume":"13","author":"YX Dai","year":"2016","unstructured":"Dai YX, Chen MH, Chen TJ, Lin MH. Patterns of psychiatric outpatient practice in Taiwan: a nationwide survey. Int J Environ Res Public Health. 2016;13(10):955. https:\/\/doi.org\/10.3390\/ijerph13100955.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"4683_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00127-018-1615-x","volume":"54","author":"MH Lee","year":"2019","unstructured":"Lee MH, Choi JW, Lee J, Shin A, Oh SM, Jung SJ, et al. Trends in prescriptions for sedative-hypnotics among Korean adults: a nationwide prescription database study for 2011\u20132015. Soc Psychiatry Psychiatr Epidemiol. 2019;54(4):477\u201384. https:\/\/doi.org\/10.1007\/s00127-018-1615-x.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"712","key":"4683_CR36","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.3399\/bjgp.2021.0054","volume":"71","author":"M Begum","year":"2021","unstructured":"Begum M, Gonzalez-Chica D, Bernardo C, Woods A, Stocks N. Trends in the prescription of drugs used for insomnia: an open-cohort study in Australian general practice, 2011\u20132018. Br J Gen Pract. 2021;71(712):e877\u201386. https:\/\/doi.org\/10.3399\/bjgp.2021.0054.","journal-title":"Br J Gen Pract"},{"key":"4683_CR37","doi-asserted-by":"publisher","unstructured":"Okui T, Park J, Hirata A, Nakashima N. Trends in the prescription of benzodiazepine receptor agonists from 2009 to 2020: a retrospective study using electronic healthcare record data of a university hospital in Japan. Healthcare (Basel). 2021;9(12). https:\/\/doi.org\/10.3390\/healthcare9121724.","DOI":"10.3390\/healthcare9121724"},{"key":"4683_CR38","unstructured":"MSD K.K., Tokyo, Japan. Belsomra\u00ae tablets 10 mg, 15 mg, 20 mg, interview form, revised December 2021 (9th Edition) (in Japanese). Available at: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/170050_1190023F1024_1_14. Accessed 20 Apr 2022."},{"issue":"1","key":"4683_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/npr2.12149","volume":"41","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M, Inada K, Enomoto M, Habukawa M, Hirose T, Inoue Y, et al. Current state of hypnotic use disorders: results of a survey using the Japanese version of Benzodiazepine Dependence Self-Report Questionnaire. Neuropsychopharmacol Rep. 2021;41(1):14\u201325. https:\/\/doi.org\/10.1002\/npr2.12149.","journal-title":"Neuropsychopharmacol Rep"},{"key":"4683_CR40","unstructured":"Ministry of Health, Labour and Welfare. Medical fee revision (in Japanese). Available at: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000106602.html. Accessed 20 Apr 2022."},{"key":"4683_CR41","first-page":"285","volume":"34","author":"K Mishima","year":"2019","unstructured":"Mishima K. Outline of the revision of medical service fees and its influence on prescription of hypnotics and anxiolytics (in Japanese). Jpn J Psych Treatment. 2019;34:285\u201391.","journal-title":"Jpn J Psych Treatment"},{"issue":"12","key":"4683_CR42","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00228-018-2531-4","volume":"74","author":"Y Schonmann","year":"2018","unstructured":"Schonmann Y, Goren O, Bareket R, Comaneshter D, Cohen AD, Vinker S. Chronic hypnotic use at 10 years\u2014does the brand matter? Eur J Clin Pharmacol. 2018;74(12):1623\u201331. https:\/\/doi.org\/10.1007\/s00228-018-2531-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10347","key":"4683_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","volume":"400","author":"F De Crescenzo","year":"2022","unstructured":"De Crescenzo F, D\u2019Al\u00f2 GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(22)00878-9.","journal-title":"Lancet"},{"issue":"11","key":"4683_CR44","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40261-019-00838-w","volume":"39","author":"Y Hirano","year":"2019","unstructured":"Hirano Y, Ii Y. Changes in prescription of psychotropic drugs after introduction of polypharmacy reduction policy in Japan based on a large-scale claims database. Clin Drug Investig. 2019;39(11):1077\u201392. https:\/\/doi.org\/10.1007\/s40261-019-00838-w.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"4683_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40268-018-0256-6","volume":"19","author":"Y Asai","year":"2019","unstructured":"Asai Y, Sano H, Miyazaki M, Iwakura M, Maeda Y, Hara M. Suvorexant (Belsomra(\u00ae) Tablets 10, 15, and 20 mg): Japanese drug-use results survey. Drugs R D. 2019;19(1):27\u201346. https:\/\/doi.org\/10.1007\/s40268-018-0256-6.","journal-title":"Drugs R D"},{"key":"4683_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.sleep.2021.11.005","volume":"89","author":"R Furihata","year":"2022","unstructured":"Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, et al. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Sleep Med. 2022;89:23\u201330. https:\/\/doi.org\/10.1016\/j.sleep.2021.11.005.","journal-title":"Sleep Med"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-023-04683-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T18:30:51Z","timestamp":1682015451000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-023-04683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4683"],"URL":"https:\/\/doi.org\/10.1186\/s12888-023-04683-2","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"30 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is not considered human subject research because it does not involve any interactions or interventions with human subjects. This is because this study utilized commercially available de-identified secondary data provided from JMDC Inc. JMDC Inc. is responsible for collecting claims data and for managing the database. All analyses were conducted by JMDC Inc. using the fixed, de-identified database, which is only accessible to the data analysts and system administrators as employees of JMDC Inc. The project deliverables comprised aggregated data, which were prepared by JMDC Inc., under a research contract with the authors. To protect privacy, patient counts below five were reported as \u201c\u2009<\u20095\u201d. No reporting of individual cases to regulatory agencies was planned as part of this retrospective observational database summarization. This study was performed in compliance with the principles enshrined in the Declaration of Helsinki as well as the Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects (Notified 23<sup>rd<\/sup> March 2021, amended 10<sup>th<\/sup> March 2022: Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare; and Ministry of Economy, Trade and Industry). Because these Japanese guidelines do not require ethics review of studies using a de-identified database comprising previously obtained secondary data, review by an Ethics Committee\/Institutional Review Board and informed consent were not required for this study or obtained for the use of these data in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SO, YY, and ST are employees of MSD K.K., Tokyo, Japan, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. ZPQ was an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may have owned stock and\/or stock options in Merck & Co., Inc., Rahway, NJ, USA at the time of the study. YH is an employee of JMDC Inc. and CI was an employee of JMDC Inc. at the time of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}